Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael A Becker

Showing results (41-50 of 57) with videos related to

Pageof 6
Sort By:
Arthritis and Rheumatism|March 8, 2005
Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with goutMichael A Becker, H Ralph Schumacher, Robert L Wortmann, et al.
The New England Journal of Medicine|December 13, 2005
Febuxostat compared with allopurinol in patients with hyperuricemia and goutMichael A Becker, H Ralph Schumacher, Robert L Wortmann, et al.
Nano Letters|November 9, 2018
Long Exciton Dephasing Time and Coherent Phonon Coupling in CsPbBr<sub>2</sub>Cl Perovskite NanocrystalsMichael A Becker, Lorenzo Scarpelli, Georgian Nedelcu, et al.
Annals of the Rheumatic Diseases|November 13, 2012
Long-term safety of pegloticase in chronic gout refractory to conventional treatmentMichael A Becker, Herbert S B Baraf, Robert A Yood, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|May 10, 2022
Evaluation of the Relationship Between Serum Urate Levels, Clinical Manifestations of Gout, and Death From Cardiovascular Causes in Patients Receiving Febuxostat or Allopurinol in an Outcomes TrialKenneth G Saag, Michael A Becker, William B White, et al.
The New England Journal of Medicine|March 13, 2018
Cardiovascular Safety of Febuxostat or Allopurinol in Patients with GoutWilliam B White, Kenneth G Saag, Michael A Becker, et al.
Arthritis and Rheumatism|September 2, 2008
Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized studyJohn S Sundy, Michael A Becker, Herbert S B Baraf, et al.
ACS Nano|June 21, 2024
Circularly Polarized Luminescence Without External Magnetic Fields from Individual CsPbBr<sub>3</sub> Perovskite Quantum DotsVirginia Oddi, Chenglian Zhu, Michael A Becker, et al.
The Journal of Rheumatology|June 7, 2007
Outcome evaluations in goutH Ralph Schumacher, William Taylor, Nancy Joseph-Ridge, et al.
Arthritis Research & Therapy|November 30, 2013
Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapyHerbert S B Baraf, Michael A Becker, Sergio R Gutierrez-Urena, et al.
Pageof 6

Showing results (41-50 of 57) with videos related to

Sort By:
Pageof 6
Arthritis and Rheumatism|March 8, 2005
Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with goutMichael A Becker, H Ralph Schumacher, Robert L Wortmann, et al.
The New England Journal of Medicine|December 13, 2005
Febuxostat compared with allopurinol in patients with hyperuricemia and goutMichael A Becker, H Ralph Schumacher, Robert L Wortmann, et al.
Nano Letters|November 9, 2018
Long Exciton Dephasing Time and Coherent Phonon Coupling in CsPbBr<sub>2</sub>Cl Perovskite NanocrystalsMichael A Becker, Lorenzo Scarpelli, Georgian Nedelcu, et al.
Annals of the Rheumatic Diseases|November 13, 2012
Long-term safety of pegloticase in chronic gout refractory to conventional treatmentMichael A Becker, Herbert S B Baraf, Robert A Yood, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|May 10, 2022
Evaluation of the Relationship Between Serum Urate Levels, Clinical Manifestations of Gout, and Death From Cardiovascular Causes in Patients Receiving Febuxostat or Allopurinol in an Outcomes TrialKenneth G Saag, Michael A Becker, William B White, et al.
The New England Journal of Medicine|March 13, 2018
Cardiovascular Safety of Febuxostat or Allopurinol in Patients with GoutWilliam B White, Kenneth G Saag, Michael A Becker, et al.
Arthritis and Rheumatism|September 2, 2008
Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized studyJohn S Sundy, Michael A Becker, Herbert S B Baraf, et al.
ACS Nano|June 21, 2024
Circularly Polarized Luminescence Without External Magnetic Fields from Individual CsPbBr<sub>3</sub> Perovskite Quantum DotsVirginia Oddi, Chenglian Zhu, Michael A Becker, et al.
The Journal of Rheumatology|June 7, 2007
Outcome evaluations in goutH Ralph Schumacher, William Taylor, Nancy Joseph-Ridge, et al.
Arthritis Research & Therapy|November 30, 2013
Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapyHerbert S B Baraf, Michael A Becker, Sergio R Gutierrez-Urena, et al.
Pageof 6